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Dear Editor, 
We believe that responsible stewardship of the bacille Calmette-Guérin (BCG) vaccine in the 
context of the COVID-19 epidemic is urgently needed. Live attenuated BCG is currently the 
only licensed vaccine to protect against tuberculosis (TB). Neonatal BCG vaccination has 
proven efficacy in protecting infants and young children against life-threatening disseminated 
forms of TB, including TB meningitis and miliary TB.1–4 Global BCG supply shortages in 
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recent years (particularly between 2014 and 2017) have highlighted the critical need to sustain 
newborn BCG vaccination, especially in settings with high TB and HIV burden.5,6 The risk 
associated with low vaccination coverage is highlighted by the dramatic increase in the 
incidence of TB meningitis in young children reported in association with BCG stock-outs.7 
Although manufacturer and supply chain issues are now largely resolved, supply remains 
fragile due to the limited number of production facilities available globally.8  
 
BCG has potential non-specific effects including putative impact on COVID-19 
In addition to protecting against TB (its intended target disease), BCG vaccination modulates 
the immune response to subsequent infections caused by other pathogensthrough the induction 
of innate immune memory and heterologous lymphocyte activation, resulting in enhanced 
cytokine production, macrophage activity, T-cell responses and antibody titres, leading to 
reduced morbidity and mortality.9 These non-specific immunological effects of BCG are used 
to treat bladder carcinoma in adults.10  
 A recent ecological study (yet to be peer-reviewed), has been widely disseminated in 
the general and social media, and claims a possible association between BCG vaccination and 
protection against severe disease and fatal outcome from SARS-CoV-2 infection (i.e., COVID-
19).11 This paper provides interesting circumstantial evidence but does not confirm causality. 
Limitations in this and similar ecological studies imply that claims suggesting potential 
protective effects of BCG against COVID-19 need to be interpreted with extreme caution. 
Potential bias in this ecological analysis includes the selection of countries and the failure to 
take into account the fact that different countries may be at different stages of the COVID-19 
epidemic. The exclusion of countries that appear to contradict the authors’ conclusions is 
unexplained. For example, BCG has not been used in Germany for the past 28 years, but 
currently has one of the lowest COVID-19-related mortality rates globally. Other high-income 
countries without universal BCG vaccination include Australia, which also has had a low 
COVID-19 mortality rate, which calls into question any association. Therefore, the suggestion 
that BCG protects against COVID-19 remains a hypothesis only, with no rigorous, peer-
reviewed scientific evidence.  
 
There is a need for research regarding the potential effects of BCG on COVID-19 
Several trials are planned to investigate whether BCG may indeed offer protection against 
COVID-19, including in healthcare workers. Such trials have already started in the Netherlands 
(BCG-CORONA; NCT04328441); in Australia (the BRACE trial; NCT04327206), where 
BCG is not routinely given to newborns; and in South Africa (TASK-008-BCG-CORONA), 
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where BCG is routinely recommended for all newborns. Outcome measures differ across these 
trials. 
 In many high TB burden countries, BCG has routinely been administered to newborns 
since the 1970s. Therefore, healthcare workers under 50 years of age are likely to have received 
BCG at birth. In these countries, healthcare workers are also commonly infected with 
Mycobacterium tuberculosis (i.e., have TB infection).12 Under these circumstances, BCG 
administration may lead to a strong local reaction at the injection site (similar to a strongly 
positive tuberculin skin test reaction). Unfortunately, as a consequence of the article by Miller 
et al,11 some healthcare workers (and members of the general public) are now requesting 
revaccination as protection for themselves and vaccination of their non-BCG-vaccinated 
dependents, especially older children. This is understandable given the fear of COVID-19. In 
this context, it is essential that we provide clear recommendations on BCG vaccination. The 
use of BCG for an unproven indication is irresponsible and may deplete BCG stocks for young 
children, for whom it has been proven to be a lifesaving preventive tool against TB-related 
morbidity and mortality.  
 
Recommendations for high TB burden settings are required 
The World Health Organization (WHO) recently issued a scientific brief calling for BCG to be 
used for neonatal BCG vaccination only in high-risk settings and not for the prevention of 
COVID-19.13 Likewise, as the co-authors on this paper – who are paediatricians, public health 
experts and researchers with many years of experience in TB and BCG – we implore you to 
protect BCG supplies for young children, for whom the vaccine offers substantial proven 
benefits. Consequently, we provide a series of recommendations (summarized in the Table).  
 First, the priority remains for neonatal BCG vaccination to be given to all infants in high 
TB burden settings. No neonate (unless clinically indicated) should leave a birthing facility 
without BCG vaccination—this should be documented in the vaccination card or the child’s 
handheld health record. Fair allocation of scarce basic resources such as BCG is crucial, and it 
is an ethical imperative that the most vulnerable should receive the greatest benefit according 
to Rawls’ theory of justice.14 Second, infants under 1 year of age who have not yet received 
BCG, require a catch-up vaccination at any health facility where BCG is available (unless there 
is a clear contra-indication), even if they are the only infant to be vaccinated from a vial and 
there is risk of wastage.1 Third, as the risk for TB meningitis and miliary TB is the highest in 
young children under 3 years of age, catch-up BCG, if missed at birth or thereafter, should be 
administered to this age group once TB infection has been excluded. This is important because 
of the severe morbidity and mortality associated with TB meningitis. Fourth, older children (>3 
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years) should not routinely receive BCG if missed at birth, although we acknowledge that 
different countries have different guidance regarding the upper age threshold, and the national 
level guidance should be followed. Fifth, BCG is ineffective as post-exposure prevention for 
TB. Following documented exposure to Mycobacterium tuberculosis, it is essential that TB 
preventive therapy is provided according to WHO and local TB guidelines. Finally, there is 
currently no compelling evidence, either for or against, that BCG protects individuals from 
COVID-19. Outside of a clinical trial, healthcare workers (or other individuals) should 
therefore not receive BCG vaccination for protection against COVID-19. Healthcare workers, 
many of whom are at high risk of COVID-19 disease, should consider enrolling in trials, 
including those where BCG is used as an intervention, if feasible. Their participation would 
generate much needed data regarding any potential benefit or risk of BCG vaccination in the 
context of COVID-19. Importantly, the BCG vaccines used for such trials should be sourced 
specifically for clinical research, and not from the limited supply available for children in low-
income settings.  
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Table  Recommendations for BCG vaccination in high TB burden settings 
 
Priority populations Further recommendations 
Neonatal BCG vaccination remains the 
priority 
National guidelines regarding the upper age 
limit for catch-up vaccination should be 
followed 
 
Unvaccinated infants should be prioritised 
for catch-up vaccination, irrespective of 
possible vaccine wastage 
 
BCG vaccination should NOT be used for 
TB prevention following TB exposure 
Children younger than 3 years who have not 
been vaccinated, should also be prioritised 
to receive catch-up vaccination once TB 
infection has been excluded 
BCG vaccination should NOT be used for 
protection against COVID-19 outside of 
a clinical trial 
 
 
TB = tuberculosis; BCG = bacille Calmette-Guérin. 
